L3VLUP
ProSign in

TVTX · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

TVTXVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • TVTX
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterTVTXVRTX
Q3 2020none listed holders, n.a.31 holders, $21.9bn
Q4 20205 holders, $183m30 holders, $18.4bn
Q1 20213 holders, $183m31 holders, $15.4bn
Q2 2021none listed holders, n.a.30 holders, $12.7bn
Q3 20213 holders, $131m35 holders, $10.1bn
Q4 20213 holders, $158m28 holders, $12.4bn
Q1 20225 holders, $150m23 holders, $16.1bn
Q2 20225 holders, $147m25 holders, $18.1bn
Q3 20225 holders, $153m22 holders, $18.4bn
Q4 20225 holders, $157m28 holders, $18.4bn
Q1 20237 holders, $259m26 holders, $21.4bn
Q2 20238 holders, $185m27 holders, $24.7bn
Q3 20232 holders, $22m33 holders, $24.3bn
Q4 20235 holders, $50m32 holders, $28.6bn
Q1 20241 holders, $1.5m31 holders, $29.8bn
Q2 20242 holders, $12m29 holders, $33.4bn
Q3 20244 holders, $75m27 holders, $33.5bn
Q4 20248 holders, $239m26 holders, $28.5bn
Q1 20257 holders, $311m21 holders, $35.4bn
Q2 20256 holders, $207m21 holders, $32.3bn
Q3 20256 holders, $340m22 holders, $25.9bn
Q4 20257 holders, $599m26 holders, $31.8bn
Q1 20264 holders, $400m25 holders, $31.8bn
Q2 20267 holders, $934m26 holders, $34.6bn
TVTX

Travere Therapeutics Inc

Holders
7
Reported value
$599m
Buyers
16
Sellers
16

Breadth 0 among 92 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
VRTX

Vertex Pharmaceuticals Inc

Holders
26
Reported value
$31.8bn
Buyers
19
Sellers
20

Breadth -1 among 92 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2025

Among the 30 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only TVTX (4)

Farallon Capital Management LLC, PDT Partners LLC, Two Sigma Investments LP, Voloridge Investment Management LLC

Only VRTX (23)

Acadian Asset Management LLC, AllianceBernstein LP, ARK Investment Management LLC, Arrowstreet Capital LP, Baillie Gifford & Co, Balyasny Asset Management LLC, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Citadel Advisors LLC, Fidelity (FMR LLC), Hudson Bay Capital Management LP, Invesco Ltd, Man Group PLC, Marshall Wace LLP, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, Squarepoint Ops LLC, T. Rowe Price Associates Inc, Wellington Management Group LLP, Winton Group Ltd, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →